APOE and Alzheimer disease: Moreover, for a given level of AD pathology, female APOE ε4 carriers may show greater levels of pathological burden, more compromised brain network integrity, and/or accelerated longitudinal decline (Altmann et al., 2014; Heise et al., 2014; Damoiseaux et al., 2012).